Drug Shortage Report for SODIUM CHLORIDE INJECTION, USP
| Report ID | 170971 |
| Drug Identification Number | 02139510 |
| Brand name | SODIUM CHLORIDE INJECTION, USP |
| Common or Proper name | SODIUM CHLORIDE INJECTION, USP |
| Company Name | FRESENIUS KABI CANADA LTD |
| Market Status | MARKETED |
| Active Ingredient(s) | SODIUM CHLORIDE |
| Strength(s) | 234MG |
| Dosage form(s) | SOLUTION |
| Route of administration | INTRAVENOUS INTRAVENOUS |
| Packaging size | 30mL |
| ATC code | B05XA |
| ATC description | I.V. SOLUTION ADDITIVES |
| Reason for shortage | Other (Please describe in comments) |
| Anticipated start date | 2022-10-03 |
| Actual start date | 2022-10-03 |
| Estimated end date | 2023-02-01 |
| Actual end date | 2023-01-31 |
| Shortage status | Resolved |
| Updated date | 2023-02-09 |
| Company comments | Product is on 100% allocation. We will be encountering a supply interruption on our Sodium Chloride Injection, USP 4 mEq/mL SD Vial 30 mL effective December 1, 2022 until February 1, 2023. Effective December 1, 2022, allocations for our Sodium Chloride Injection, USP 4 mEq/mL Maxivial® 100 mL will be increased. Contract customers will be allocated 100% of historical 100 mL demand plus 100% of historical 30 mL demand on a 1:2 ratio (1 vial of 100 mL = 2 vials of 30 mL). |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 165 GALAXY BLVD, SUITE 100 TORONTO, ONTARIO CANADA M9W 0C8 |
| Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v9 | 2023-02-09 | French | Compare |
| v8 | 2023-02-09 | English | Compare |
| v7 | 2022-11-11 | French | Compare |
| v6 | 2022-11-11 | English | Compare |
| v5 | 2022-11-03 | French | Compare |
| v4 | 2022-11-03 | English | Compare |
| v3 | 2022-10-04 | English | Compare |
| v2 | 2022-10-03 | French | Compare |
| v1 | 2022-10-03 | English | Compare |
Showing 1 to 9 of 9